acitretin "orifarm" 10 mg kapsler, hårde
orifarm generics a/s - acitretin - kapsler, hårde - 10 mg
acitretin "orifarm" 25 mg kapsler, hårde
orifarm generics a/s - acitretin - kapsler, hårde - 25 mg
kenalog 40 mg/ml injektionsvæske, suspension
orifarm a/s - triamcinolonacetonid - injektionsvæske, suspension - 40 mg/ml
sevofluran "baxter" 1 ml/ml væske til inhalationsdamp
baxter a/s - sevofluran - væske til inhalationsdamp - 1 ml/ml
zofenil comp. 30+12,5 mg filmovertrukne tabletter
menarini international operation - hydrochlorthiazid, zofenoprilcalcium - filmovertrukne tabletter - 30+12,5 mg
neemazal t/s (dispensation 2014-2016) emulsionskoncentrat
trifolio-m gmbh - azadirachtin - emulsionskoncentrat - 10 g/l azadirachtin
prepandemic influenza vaccine (h5n1) (split virion, inactivated, adjuvanted) glaxosmithkline biologicals
glaxosmithkline biologicals s.a. - splittet influenzavirus, inaktiveret, indeholdende antigen: a / vietnam / 1194/2004 (h5n1) som brugt belastning (nibrg-14) - influenza, human; immunization; disease outbreaks - vacciner - aktiv immunisering mod h5n1-subtype af influenza a-virus. denne angivelse er baseret på immunogenicitet data fra raske forsøgspersoner i alderen fra 18 år og op efter administration af to doser vaccine, der er fremstillet af en/vietnam/1194/2004 nibrg-14 (h5n1) (se afsnit 5. prepandemic influenza vaccine (h5n1) (split virion, inaktiveret, adjuvanted) glaxosmithkline biologicals 3. 75 µg bør anvendes i overensstemmelse med officielle retningslinjer.
kenalog 40 mg/ml injektionsvæske, suspension
bristol-myers squibb ab - triamcinolonacetonid - injektionsvæske, suspension - 40 mg/ml
triamcinolonacetonid "paranova" 40 mg/ml injektionsvæske, suspension
paranova danmark a/s - triamcinolonacetonid - injektionsvæske, suspension - 40 mg/ml
ronapreve
roche registration gmbh - casirivimab, imdevimab - covid-19 virus infection - immune sera og immunoglobuliner, - ronapreve is indicated for:treatment of covid-19 in adults and adolescents aged 12 years and older weighing at least 40 kg who do not require supplemental oxygen and who are at increased risk of progressing to severe covid-19 (see section 4. prevention of covid-19 in adults and adolescents aged 12 years and older weighing at least 40 kg (see section 4. the use of ronapreve should take into account information on the activity of ronapreve against viral variants of concern. se afsnit 4. 4 og 5.